Initial Treatment with Transplantation for Patients with Multiple Myeloma

Consolidation with autologous stem-cell transplantation significantly improved progression-free survival versus triplet induction therapy alone.

Improved efficacy in the initial treatment of patients with multiple myeloma has raised the possibility of eliminating the current standard of consolidation with high-dose melphalan and autologous stem cell transplantation (ASCT).

European investigators have now conducted an industry-sponsored, prospective, randomized phase III clinical trial involving 700 newly diagnosed myeloma patients (age, <65 years) who received triplet therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for 3 cycles, followed by stem-cell mobilization and collection. Patients were randomized 1:1 to ASCT followed by another 2 cycles of RVD versus an additional RVD for 5 cycles without ASCT; 92% of those assigned to ASCT underwent the procedure as planned. Al…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Initial Treatment with Transplantation for Patients with Multiple Myeloma

Topics

Reviewing Author